Protara Therapeutics (NASDAQ:TARA – Get Free Report) had its price objective increased by Oppenheimer from $26.00 to $30.00 in a research note issued on Monday, Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Separately, HC Wainwright restated a “buy” rating and set a $23.00 price objective on shares of Protara Therapeutics […]